| Group | Control group (n = 33) | Leflunomide group (n = 34) | Tofacitinib group (n = 28) | P value |
| Women (Example (%)) | 27 (81.8) | 29 (85.3) | 23 (82.1) | 0.063 |
| Age (age) | 57.4 ± 10.5 | 59.2 ± 8.9 | 59.3 ± 12.9 | 0.735 |
| The course of disease (month) | 87.2 ± 92.2 | 76.9 ± 71.3 | 82.6 ± 100.1 | 0.520 |
| ESR (mm/h) | 62.7 ± 30.4 | 67.6 ± 32.3 | 64.8 ± 23.6 | 0.253 |
| CRP (ug/ml) | 31.4 ± 30.1 | 34.2 ± 34.5 | 29.9 ± 28.9 | 0.564 |
| RF (IU/ml) | 177.0 ± 171.5 | 196.0 ± 161.8 | 186.7 ± 244.9 | 0.922 |
| Anti-CCP antibody | 39.4 ± 22.4 | 36.8 ± 25.0 | 32.5 ± 21.3 | 0.458 |
| HGB (g/L) | 106.0 ± 14.3 | 101.0 ± 14.3 | 100.0 ± 13.4 | 0.166 |
| AST (U/L) | 20.2 ± 8.6 | 18.6 ± 7.9 | 18.4 ± 6.5 | 0.611 |
| ALT (U/L) | 20.0 ± 20.1 | 16.8 ± 16.8 | 15.5 ± 10.1 | 0.533 |
| DAS28-ESR | 5.7 ± 2.6 | 5.5 ± 2.0 | 6.1 ± 2.2 | 0.742 |
| MSUS score | 10.4 ± 3.2 | 9.6 ± 3.9 | 9.8 ± 3.8 | 0.641 |